Moreover, the synergistic anti-tumor activity of an anti-PD-1 antibody in combination with PB-020, a novel PPP-derived small-molecule inhibitor of IGF1R with improved pharmacokinetic properties, has been demonstrated in a mouse model of colorectal cancer (102). Here, IGF1R is linked to neoplasm.